Email this article Correctness of use of microdosed combination oral contraceptives in young women
- Authors: Buralkina NA1
-
Affiliations:
- V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 4 (2017)
- Pages: 26-29
- Section: Articles
- URL: https://journals.rcsi.science/2079-5831/article/view/28631
- ID: 28631
Cite item
Abstract
The article describes the effective use of a microdosed combined oral contraceptive containing drospirenone in young women. The use of synthetic progestin IV generation due to antiandrogenic and unique antimineralocorticoid effects makes it possible to obtain an additional spectrum of medicinal properties, has a high contraceptive effectiveness, is well tolerated, reduces the symptoms of premenstrual syndrome, acne, and seborrhea with virtually no effect on body weight in young women.
Full Text
##article.viewOnOriginalSite##About the authors
N A Buralkina
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation
Email: natalyaburalkina@yandex.ru
д-р мед. наук, ст. науч. сотр. хирургического отд-ния, доц. каф. ФГБУ «НМИЦАГиП им. акад. В.И.Кулакова» 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
References
- Элкинд Д.Эрик Эриксон и восемь стадий человеческой жизни (предисловие). В кн.: Эриксон Э.Г. Детство и общество. 1996; с. 6-22.
- Шаповаленко И.В. Возрастная психология. М., 2007.
- Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс - информ, 2006.
- Mosher W.D et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; 350: 1-36.
- Elger W, Beier S, Pollow K et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68: 891-905.
- Fuhrmann U, Krattenmacher R, Slater E.P, Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Сontraception 1996; 54: 243-51.
- Keam S.J, Wagstaff A.J. ADIS Drug Evaluation. Treat Endocrinol 2003; 2: 49.
- Rapkin A.J, Winer S.A. Drospirenone: a novel progestin. Exp Opin Pharmacother 2007; 8: 989-99.
- Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008; 61: 151-7.
- Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280: 255-61.
- Прилепская В.Н. Руководство по контрацепции. 2-е изд. М.: МЕДпресс - информ, 2010; с. 55-60.
- Romualdi D, Cicco S, Busacca M et al. Clinical efficacy and metabolic impact of two different dosages of ethinyl - estradiol in association with drospirenone in normal - weight women with polycystic ovary syndrome: A randomized study. J Endocrinol Invest 2013; 36 (8): 636-41.
- Хащенко Е.П., Уварова Е.В., Буралкина Н.А. и др. Возможности терапии косметологических проявлений у девочек с синдромом поликистозных яичников. Репродуктивное здоровье детей и подростков. 2015; 6: 41-7.
- Schindler A.E, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2008; 61: 171-80.
- Suthipongse W, Taneepanichskul S. An open - label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. Contraception 2004; 69: 23-6.
- Контрацепция сегодня. Мнение экспертов. Актуальное интервью. Женская консультация. 2012; 14 (13).
Supplementary files
